KRAS and colorectal carcinoma: Although anti-EGFR treatment is not effective in CRC patients with mutated KRAS, Ruzzo et al. reported that the upregulation of let-7a may rescue the sensitivity of anti-EGFR therapies in such CRC patients [79].